title: Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.
abstract: The objective of our study was to investigate whether an interaction exists between apolipoprotein E (APOE) genotype and the response of patients with Alzheimer's disease (AD) to selegiline treatment, and whether APOE genotype independently affects the rate of AD progression. A 48-week multicenter double-blind trial was undertaken on 43 patients with mild to moderate AD. Primary efficacy measures were the AD Assessment Scale (ADAS), an 11-item cognitive subscale of ADAS (ADAS-Cog/11) and the Mini Mental State Examination. Secondary outcome measures were Clinical Global Impression of severity and CGI of change scales. The therapeutic response to selegiline was not affected by APOE genotype. Our results revealed that the APOE4 allele carrier AD probands did not respond better to selegiline treatment than the APOE2-3 patients, i.e. APOE status did not influence the therapeutic outcome of selegiline treatment.
authors.affiliation: Department of Psychiatry, Albert Szent-Györgyi Center for Medical and Pharmaceutical Sciences, Faculty of Medicine, University of Szeged, Semmelweis u.6, H-6725 Szeged, Hungary. kalmanj@nepsy.szote.u-szeged.hu
authors.forename: János
authors.initials: J
authors.lastname: Kálmán
authors.forename: Anna
authors.initials: A
authors.lastname: Juhász
authors.forename: Agnes
authors.initials: A
authors.lastname: Rimanóczy
authors.forename: András
authors.initials: A
authors.lastname: Palotás
authors.forename: Miklós
authors.initials: M
authors.lastname: Palotás
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szabó
authors.forename: Krisztina
authors.initials: K
authors.lastname: Boda
authors.forename: János
authors.initials: J
authors.lastname: Márki-Zay
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Janka
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics*; D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D004311:Double-Blind Method; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D011446:Prospective Studies; D012642:Selegiline / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D053329:Apolipoprotein E2; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D018696:Neuroprotective Agents; D012642:Selegiline